Genomic alterations to predict response to irinotecan-based chemotherapy in metastatic colorectal cancer.

被引：0
|
作者：
De La Fouchardiere, Christelle
Jiang, Xiaojun
Pissaloux, Daniel
Seigne, Christelle
Wang, Qing
Desseigne, Francoise
Fondrevelle, Marie-Eve
Cassier, Philippe Alexandre
Attignon, Valery
Combaret, Valerie
Perol, David
Tredan, Olivier
Blay, Jean-Yves
机构：
[1] Ctr Leon Berard, F-69373 Lyon, France
[2] Ctr Leon Berard, Dept Med Oncol, F-69373 Lyon, France
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 03期
关键词：
D O I：
10.1200/jco.2015.33.3_suppl.586
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
586
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Pharmacogenetic Tailoring of Irinotecan-based First-line Chemotherapy in Metastatic Colorectal Cancer: Results of a Pilot Study
    Freyer, Gilles
    Duret, Aude
    Milano, Gerard
    Chatelut, Etienne
    Rebischung, Christine
    Delord, Jean-Pierre
    Merrouche, Yacine
    Lledo, Gerard
    Etienne, Marie-Christine
    Falandry, Claire
    ANTICANCER RESEARCH, 2011, 31 (01) : 359 - 366
  • [32] Association of CHFR and WRN promotor methylation and clinical benefit from irinotecan-based chemotherapy for metastatic colorectal cancer
    Kim, S. Y.
    Dong, S. M.
    Yeo, H. Y.
    Baek, J. Y.
    Shim, E. K.
    Ku, J. Y.
    Chang, H. J.
    ANNALS OF ONCOLOGY, 2015, 26 : 51 - 51
  • [33] The value of genetic polymorphisms to predict toxicity in metastatic colorectal patients with irinotecan-based regimens.
    Lamas, M. J.
    Duran, G.
    Balboa, E.
    Candamio, S.
    Bernardez, B.
    Carracedo, A.
    Lopez, R.
    Barros, F.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [34] Irinotecan-based combination chemotherapy for metastatic small intestinal adenocarcinoma
    Shibata, Yoshihiro
    Baba, Eishi
    Ariyama, Hiroshi
    Arita, Shuji
    Isobe, Taichi
    Kusaba, Hitoshi
    Mitsugi, Kenji
    Nakano, Shuji
    Akashi, Koichi
    ONCOLOGY LETTERS, 2010, 1 (03) : 423 - 426
  • [35] Irinotecan as a second line chemotherapy in advanced and metastatic colorectal cancer. Is that appropriate regimen?
    Chilikidi, KY
    Lazarev, AF
    Doty, IN
    CLINICAL CANCER RESEARCH, 1999, 5 : 3775S - 3775S
  • [36] Irinotecan-based chemotherapy in a metastatic colorectal cancer patient under haemodialysis for chronic renal dysfunction:: two cases considered
    Venat-Bouvet, Laurence
    Saint-Marcoux, Franck
    Lagarde, Christian
    Peyronnet, Pierre
    Lebrun-Ly, Valerie
    Tubiana-Mathieu, Nicole
    ANTI-CANCER DRUGS, 2007, 18 (08) : 977 - 980
  • [37] Association between mismatch repair gene and irinotecan-based chemotherapy in metastatic colon cancer
    Ma, Junli
    Zhang, Yan
    Shen, Hong
    Kapesa, Linda
    Liu, Wenqiang
    Zeng, Mengsi
    Zeng, Shan
    TUMOR BIOLOGY, 2015, 36 (12) : 9599 - 9609
  • [38] Complete response of brain metastases to irinotecan-based chemotherapy
    Chou, R
    Chen, A
    Lau, D
    JOURNAL OF CLINICAL NEUROSCIENCE, 2005, 12 (03) : 242 - 245
  • [39] Handy prognostic model in patients with oxaliplatin-based or irinotecan-based first-line chemotherapy for metastatic colorectal cancer
    Chibaudel, B.
    Tournigand, C.
    Bonnetain, F.
    Andre, T.
    Lledo, G.
    Maindrault-Goebel, F.
    Larsen, A. K.
    Louvet, C.
    de Gramont, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [40] CHFR-Promoter-Methylation Status Is Predictive of Response to Irinotecan-based Systemic Chemotherapy in Advanced Colorectal Cancer
    Hagiwara, Toshiaki
    Sugimoto, Kiichi
    Momose, Hirotaka
    Irie, Takahiro
    Honjo, Kumpei
    Okazawa, Y. U.
    Kawai, Masaya
    Kawano, Shingo
    Munakata, Shinya
    Takahashi, Makoto
    Kojima, Yutaka
    Serizawa, Nobuko
    Nagahara, Akihito
    Hoffman, Robert M.
    Brock, Malcolm, V
    Sakamoto, Kazuhiro
    ANTICANCER RESEARCH, 2022, 42 (02) : 697 - 707
12345